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and cAMP-dependent signaling mechanisms
Heather L Francis1,2,3, Sharon DeMorrow1,2, Antonio Franchitto4,5, Julie K Venter2, Romina A Mancinelli4,
Mellanie A White2, Fanyin Meng2,3, Yoshiyuki Ueno6, Guido Carpino7, Anastasia Renzi1,4, Kimberly K Baker3,
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Although large cholangiocytes exert their functions by activation of cyclic adenosine 30,50-monophosphate (cAMP),
Ca2þ -dependent signaling regulates the function of small cholangiocytes. Histamine interacts with four receptors,
H1–H4HRs. H1HR acts by Gaq activating IP3/Ca
2þ , whereas H2HR activates Gas stimulating cAMP. We hypothesize that
histamine increases biliary growth by activating H1HR on small and H2HR on large cholangiocytes. The expression of
H1–H4HRs was evaluated in liver sections, isolated and cultured (normal rat intrahepatic cholangiocyte culture (NRIC))
cholangiocytes. In vivo, normal rats were treated with histamine or H1–H4HR agonists for 1 week. We evaluated: (1)
intrahepatic bile duct mass (IBDM); (2) the effects of histamine, H1HR or H2HR agonists on NRIC proliferation, IP3 and
cAMP levels and PKCa and protein kinase A (PKA) phosphorylation; and (3) PKCa silencing on H1HR-stimulated NRIC
proliferation. Small and large cholangiocytes express H1–H4HRs. Histamine and the H1HR agonist increased small IBDM,
whereas histamine and the H2HR agonist increased large IBDM. H1HR agonists stimulated IP3 levels, as well as PKCa
phosphorylation and NRIC proliferation, whereas H2HR agonists increased cAMP levels, as well as PKA phosphorylation
and NRIC proliferation. The H1HR agonist did not increase proliferation in PKCa siRNA-transfected NRICs. The activation of
differential signaling mechanisms targeting small and large cholangiocytes is important for repopulation of the biliary
epithelium during pathologies affecting different-sized bile ducts.
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Cholangiocytes, which line intrahepatic and extrahepatic bile
ducts,1,2 modify canalicular bile while it is being delivered
from the bile canaliculus to the small intestine.3,4 Secretin
stimulates secretion of ductal bile by interaction with secretin
receptors (SRs)1,3 that increases the synthesis of cyclic ade-
nosine 30,50-monophosphate (cAMP), phosphorylation
of protein kinase A (PKA), opening of cystic fibrosis
transmembrane conductance regulator with subsequent
activation of the Cl/HCO3
 anion exchanger 2 (AE2),
leading to enhanced bicarbonate secretion into bile.1,3,5–7
Cholangiocytes, which are constitutively mitotically dor-
mant,8,9 markedly proliferate or are damaged in human
cholangiopathies10 and in animal models of cholestasis,
including bile duct ligation (BDL) and acute carbon
tetrachloride (CCl4) administration.
11 As cholangiocytes are
the only cells expressing SR in the rodent liver,12 changes in
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the expression of this receptor are key for functionally
evaluating the degree of biliary growth/loss.3,8,9,11,13,14 For
example, treatment of normal rats with forskolin induces
cholangiocyte hyperplasia and increases secretin-stimulated
choleresis13 that is similar to that seen in the BDL model.3 In
models of biliary damage (eg, after acute CCl4 administra-
tion), there is loss of secretin-stimulated ductal secretion.11
Models of biliary proliferation/loss are critically important
to better understand the development of cholangiopathies,
including primary biliary cirrhosis and primary sclerosing
cholangitis. Two main signaling pathways are important for
regulating cholangiocyte proliferation: the IP3/Ca
2þ - and the
cAMP-dependent signaling pathways.8,9,11,14–16 These two
signaling pathways regulate both small (IP3/Ca
2þ ) and large
(cAMP) cholangiocyte growth/loss in rodent models of
cholestasis.8,9,11,14–16
Histamine is derived from the conversion of histidine to
histamine through the enzyme L-histidine decarboxylase,17
and interacts with four G protein-coupled receptors: H1HR,
H2HR, H3HR and H4HR.18,19 Although endogenous hista-
mine elicits a proliferative effect in different cell types,20,21 the
four histamine receptors (HRs) interact with independent G
proteins to stimulate varying signaling pathways producing
varying effects on cells.22 The H1HR couples to Gaq mobi-
lizing Ca2þ -dependent signaling in a number of cells
including cholangiocytes,15,22 whereas the H2HR mainly
interacts with Gas stimulating a cAMP-dependent pathway.
23
These two receptors stimulate the growth of numerous
cell types, including cholangiocytes.15,21 This is in contrast
to H3 and H4HRs that have inhibitory effects on cell
growth (including cholangiocytes)16 by Gai coupling that
inhibits cAMP synthesis.16 In our study, we tested the
hypotheses that (1) histamine stimulates cholangiocyte pro-
liferation of normal rats and (2) an H1HR agonist stimulates
the proliferation of small cholangiocytes by activation of
IP3/Ca
2þ signaling, whereas H2HR agonists increase the
proliferation of large cholangiocytes by an intracellular
mechanism requiring the activation of cAMP-dependent
signaling.
MATERIALS AND METHODS
Materials
Reagents were purchased from Sigma Chemical (St Louis,
MO), unless otherwise indicated. The HR agonists, histamine
trifluoromethyl toluidide (HTMT dimaleate, H1HR ago-
nist),15 amthamine dihydrobromide (H2HR agonist)24 and
(R)-(a)-(-)-methylhistamine dihydrobromide (RAMH, a
H3HR agonist)16 were obtained from Tocris Bioscience
(Ellisville, MO). The monoclonal mouse antibody against
proliferating cellular nuclear antigen (PCNA, clone PC10,
cat. no. M0879) was purchased from Dako (Kyoto, Japan).
The substrate for g-glutamyl transpeptidase (g-GT), N-(g-L-
glutamyl)-4-methoxy-2-naphthylamide was purchased from
Polysciences (Warrington, PA). Antibodies for HR subtypes
were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA), and previously used in rat liver sections and in rat and
mouse cholangiocytes.15,16 In particular, H1HR (clone A-20,
cat. no. sc-33970) is an affinity-purified goat polyclonal
antibody raised against a peptide mapping within a cyto-
plasmic domain of H1HR of human origin. H2HR (clone
H-70, cat. no. sc-50314) is a rabbit polyclonal antibody raised
against amino acids 290–359 mapping within a C-terminal
cytoplasmic domain of H2HR of human origin. H3HR
(clone C-20, cat. no. sc-17921) is an affinity-purified goat
polyclonal antibody raised against a peptide mapping near
the C terminus of H3HR of human origin. H4HR (clone
Q-20, cat. no. sc-33965) is an affinity-purified goat poly-
clonal antibody raised against a peptide mapping within a
cytoplasmic domain of H4HR of human origin. The goat
polyclonal affinity-purified phosphorylated-PKCa antibody
(Ser 657, cat. no. sc-12356) was raised against a short amino-
acid sequence containing phosphorylated Ser 657 of PKCa
of human origin (Santa Cruz Biotechnology). PKCa (H-7,
sc-8393) is a mouse monoclonal antibody specific for an
epitope mapping between amino acids 645 and 672 at the C
terminus of PKCa of human origin (Santa Cruz Biotech-
nology). The goat polyclonal affinity-purified pPKA IIa reg
antibody (Ser 96, sc-12905-R) was raised against a short
amino-acid sequence containing phosphorylated Ser 96 of
p-PKA IIa reg of human origin (Santa Cruz Biotechnology).
The PKAa cat affinity-purified rabbit polyclonal antibody
(C-20, sc-903, Santa Cruz Biotechnology) against total PKA
was raised against a peptide mapping at the C terminus
of PKAa cat of human origin. The RNeasy mini kit to
purify total RNA from cholangiocytes was purchased from
Qiagen (Valencia, CA). The RIA kits for measurement of
intracellular cAMP ([125I] Biotrak Assay System, RPA509)
and IP3 (D-myo-inositol 1,4,5-trisphosphate (IP3) [
3H] Bio-
trak Assay System, TRK1000) levels were purchased from GE
Healthcare (Piscataway, NJ).
Experimental Models
Male Fisher rats (weighing 150–175 g) were purchased
from Charles River (Wilmington, MA) and maintained in a
temperature-controlled environment (20–221C) with 12:12-h
light–dark cycles. Animals were fed ad libitum standard
chow and had free access to drinking water. Our studies
were performed in normal rats treated by daily IP injections
with vehicle (0.9% NaCl), histamine (0.5mg/kg of BW),25
HTMT dimaleate (H1HR agonist, 0.5mg/kg of BW),26 amth-
amine dihydrobromide (H2HR agonist, 0.5mg/kg of BW),27
RAMH (H3HR agonist, 10mg/kg of BW)16 or the H4HR
agonist, clobenpropit (10mg/kg of BW)28 for 1 week. Before
each experimental procedure, animals were injected with
sodium pentobarbital (50mg/kg weight, IP). Study proto-
cols were performed in compliance with the institutional
guidelines set forth by the Institutional Animal Care and
Use Committee (Scott and White Texas A&M Health Science
Center).
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Purified Cholangiocytes and Normal Rat Intrahepatic
Cholangiocyte Cultures
Virtually pure cholangiocytes were isolated by immunoaffinity
separation13,16,29 with a monoclonal antibody (a gift from
Dr R Faris) against an unidentified antigen expressed by all
intrahepatic rat cholangiocytes.29 Cell count and viability
(B97%) were measured by trypan blue exclusion. Purity
(B99%) was assessed by histochemistry for g-GT.30 The
in vitro experiments were performed in freshly isolated
cholangiocytes and our polarized normal rat intrahepatic
cholangiocyte culture (NRICs).31 Cell number and frequency
distribution of NRIC were measured using an automated cell
counter (Cellometer Auto T4, Nexcelom Bioscience).32
Assessment of Histamine Receptor Expression
We evaluated the expression of HR subtypes by (1)
immunohistochemistry15,33 in normal liver sections; (2)
immunofluorescence15 in NRIC smears; and (3) RT-PCR15
(1 mg total RNA) and immunoblots (10 mg protein) from
freshly isolated normal cholangiocytes and NRICs.
Immunohistochemistry in liver sections with the selected HR
antibodies (1:100 dilution) was performed as described pre-
viously.15,16 For all immunoreactions, negative controls (with
pre-immune serum substituted for the primary antibody)
were included. Light microscopy photographs of liver sec-
tions were taken by Leica Microsystems DM 4500 B Light
Microscopy (Leica Microsystems, Weltzlar, Germany) using a
Jenoptik Prog Res C10 Plus Videocam (Jena, Germany).
Immunofluorescence for HR subtypes in NRICs was per-
formed as described previously.15 After staining, images were
visualized using a confocal microscope (Olympus IX-71;
Olympus, Tokyo, Japan). For all immunoreactions, appro-
priate negative controls were used.
Standard RT-PCR conditions were used for measurement
of the mRNA expression for H1–H4R in pooled cholangio-
cytes (formed by small and large cholangiocytes)31 and
NRICs: 10min at 951C, 15 s at 951C, 30 s at 551C and 30 s at
721C, 30 cycles at 41C. Specific primers designed against the
rat H1HR (NM_000861, expected fragment length 157 bp),
H2HR (NM_022304, expected fragment length 181bp), H3HR
(NM_053506, expected fragment length 180 bp), H4HR
(NM_131909, expected fragment length 181 bp) and glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH, NM_002046,
the housekeeping gene,34 expected fragment length 175 bp)
were purchased from (SABiosciences, Frederick, MD). We
used RNA from the rat brain and water as positive and
negative controls, respectively. The protein expression of
H1–H4HR was measured by immunoblots in protein (10mg)
lysates from the brain (positive control) and isolated small and
large normal cholangiocytes. Immunoblots were normalized
by b-actin.15,16
In Vivo Studies Evaluation of the Intrahepatic Bile Duct
Mass of Small, Large and Pooled Ducts
In the selected groups of animals, cholangiocyte growth was
measured in liver sections (4 mm thick) by evaluation of the
percentage of intrahepatic small, large and pooled bile ducts
stained for cytokeratin-19 (CK-19, a specific marker of the
biliary epithelium).9,34 In each liver section, IBDM was
measured as area occupied by CK-19-positive bile duct/total
area 100.35 Sections were analyzed using a BX-51 light
microscope (Olympus) with a video cam (Spot Insight;
Diagnostic Instrument Inc., Sterling Heights, MI) and pro-
cessed using an Image Analysis System (IAS: Delta Sistemi,
Rome, Italy).
Cholangiocyte proliferation was also evaluated by im-
munoblots for PCNA14 in protein (10 mg) lysates from the
spleen (positive control) and isolated cholangiocytes from
the selected experimental groups. Immunoblots were nor-
malized by b-actin.15,16 Band intensity was determined by
scanning video densitometry using the phospho-imager,
Storm 860 (GE Healthcare) and the ImageQuant TL software
version 2003.02 (GE Healthcare, Little Chalfont, Buck-
inghamshire, England).
Effect of In Vivo Administration of Histamine on Basal-
and Secretin-Stimulated Bile and Bicarbonate Secretion
and cAMP levels
We measured the effect of chronic in vivo administration of
histamine to normal rats on basal- and secretin-stimulated
bile secretion (in bile fistula rats)3,9 and cAMP levels
(in purified cholangiocytes),13,14,16 two functional para-
meters of cholangiocyte proliferation.3,9,13,14 After anesthesia,
rats were surgically prepared for bile collection as described
previously.3,9 When steady-state bile flow was reached
(60–70min from the intravenous infusion of Krebs–Ringer–
Henseleit solution, KRH), rats were infused with secretin
(100 nM) for 30min, followed by intravenous infusion of
KRH for 30min. Bicarbonate concentration in bile was de-
termined using an ABL 520 Blood Gas System (Radiometer
Medical A/S, Copenhagen, Denmark).
After purification, cholangiocytes (1 105 cells) were
incubated at 371C for 1 h (to regenerate membrane proteins
damaged by proteolytic enzymes during cell isolation)5 and
subsequently stimulated at room temperature for 5min with
0.2% bovine serum albumin (BSA) or secretin (100 nM
solution containing 0.2% BSA) before evaluation of cAMP
levels by RIA.13,14,16
In Vitro Studies Evaluation of Cholangiocyte
Proliferation and Signaling Mechanisms
Effects of histamine, H1HR or H2HR agonists (in the ab-
sence or presence of specific HR antagonists or inhibitors of
IP3/Ca
2þ or cAMP signaling) on cholangiocyte proliferation
and signaling mechanisms were evaluated in NRICs.31 To
evaluate dose and time dependency, NRICs were treated with
0.2% BSA (basal) or histamine (10, 50 and 100 mM) for 24
and 48 h before evaluating cell proliferation using the
CellTiter 96 Aqueous One Solution Cell Proliferation
Assay (MTS)15 (see above). In separate sets of experiments,
NRICs were treated at 371C for 24 h with: (1) 0.2% BSA; (2)
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histamine (10 mM) in the absence or presence of pre-
incubation with terfenadine (H1HR antagonist, 10 mM),15
or cimetidine (H2HR antagonist, 10 mM)36 or terfenadi-
neþ cimetidine (both at 10 mMþ histamine, 10 mM); or (3)
HTMT dimaleate (H1HR agonist, 10 mM),15 amthamine
dihydrobromide (H2HR agonist, 10 mM),37 RAMH (H3HR
agonist, 10 mM)16 or clobenpropit (H4HR agonist, 10 mM)37
before evaluation of proliferation by MTS assays.15 To
determine whether the stimulatory effects of histamine (the
endogenous neurotransmitter) on NRIC proliferation are
mediated by activation of H1 (mediated by Ca2þ signaling)
and/or H2 (regulated by cAMP signaling) HRs, we stimulated
NRICs at 371C for 24 h with (1) 0.2% BSA; (2) histamine
(10 mM); or (3) HTMT dimaleate (10 mM),15 or amthamine
dihydrobromide (10 mM)37 in the absence or presence of pre-
incubation with BAPTA/AM (5 mM),15 Go¨6976 (1 mM, Ca2þ -
dependent PKCa inhibitor)38 or Rp-cAMPs (100 mM, PKA
inhibitor).13
Measurement of IP3 and cAMP Levels and
Phosphorylation of PKC and PKA
We performed experiments in NRICs aimed to demonstrate
that HTMT dimaleate increases IP3 levels and PKC phos-
phorylation, whereas amthamine dihydrobromide enhances
cAMP levels and PKA phosphorylation. For evaluation
of cAMP levels, NRICs were treated at room temperature
for 5min5,13 with (1) 0.2% BSA or (2) HTMT dimaleate
(10 mM)15 or amthamine dihydrobromide (10 mM) before
evaluation of cAMP levels by RIA.5,13 For measurements of
IP3 levels, NRICs were treated at room temperature for
10min with (1) 0.2% BSA or (2) HTMT dimaleate (10 mM)15
or amthamine dihydrobromide (10 mM) before evaluation of
IP3 levels by RIA.
15
Before evaluation of phosphorylation of PKC or PKA,39
NRICs were treated at room temperature for 90min with (1)
0.2% BSA or (2) HTMT dimaleate (10 mM)15 or amthamine
dihydrobromide (10 mM).37
Effect of PKCa Silencing on NRIC Proliferation
As (1) IP3/Ca
2þ -dependent PKCa has a key role in the
regulation of cholangiocyte functions14,39,40 and (2) HTMT
dimaleate increases IP3 levels and PKCa phosphorylation
(see the ‘Results’ section), we evaluated the effect of PKCa
silencing on NRIC proliferation after treatment of these cells
with HTMT dimaleate. NRICs were plated into 6-well plates
and allowed to adhere overnight. siRNA transfection (0.25–
1 mg of PKCa siRNA was used) was performed according to
the instructions provided by Santa Cruz Biotechnology.
Diluted siRNA duplexes were added to the cells and allowed
to incubate for 5 h at 371C in a CO2 incubator. For controls, a
scrambled siRNA duplex (Santa Cruz Biotechnology) was
added to corresponding wells. The extent of PKCa silencing
was evaluated by measuring the protein expression of total
PKCa in transfected vs control NRICs by immunoblots (see
above).15 PCNA protein expression was evaluated in NRIC
cells treated with 0.2% BSA or HTMT dimaleate (10 mM) for
24 h in the absence or presence of PKCa siRNA (1.0 mg).
Statistical Analysis
All data are expressed as mean±s.e.m. Differences between
groups were analyzed by Student’s unpaired t-test when two
groups were analyzed and ANOVA when more than two
groups were analyzed, followed by an appropriate post hoc
test.
RESULTS
Histamine Receptor Expression
By immunohistochemistry in liver sections, both small
(yellow arrow) and large (red arrow) bile ducts express the
four HR subtypes (H1–H4HRs) (Figure 1a). By immuno-
fluorescence, NRICs (which are formed by small and large
cholangiocytes as evaluated by frequency size distribution)31
(Figure 1b) expressed the four HRs (Figure 1b). DAPI
staining is seen in blue, whereas the red staining represents
the specific HR. A merged image is also supplied along with
negative staining (Figure 1b). By RT-PCR, purified pooled
(containing small and large cells) cholangiocytes from nor-
mal rats and NRICs expressed H1–H4HRs (Figure 1c). In
addition, by immunoblots, purified small and large normal
cholangiocytes expressed H1–H4HRs (Figure 1c).
Evaluation of Intrahepatic Bile Duct Mass
Chronic administration of histamine and the H1HR agonist,
HTMT dimaleate, increased small IBDM of normal rats
compared with saline-treated rats (Figure 2a); the H2HR
agonist, amthamine dihydrobromide, did not alter small
IBDM (Figure 2a). Histamine and amthamine dihydro-
bromide (but not HTMT dimaleate) increased large IBDM of
normal rats compared with control rats (Figure 2b). Hista-
mine, the H1 and the H2HRs agonists increased overall
IBDM (Figure 2a–c). No changes were observed when nor-
mal rats were treated with RAMH or clobenpropit (not
shown). There was a significant increase in PCNA protein
expression in freshly isolated pooled cholangiocytes from
normal rats treated with histamine, H1HR or H2HR agonists
compared with vehicle-treated rats (Figure 2d). These results
rule out the potential role of the H3HR and H4HR agonists
in activating cholangiocyte proliferation.
Effect of In Vivo Administration of Histamine on Basal-
and Secretin-Stimulated Bile and Bicarbonate Secretion
and cAMP Levels
Secretin increased intracellular cAMP levels in cholangiocytes
from normal rats treated with saline (Figure 3). Chronic
in vivo administration of histamine to normal rats increased
both basal- and secretin-stimulated cAMP levels of cho-
langiocytes (a functional index of biliary growth)3,11,14
compared with their corresponding values of purified cho-
langiocytes from saline-treated normal rats (Figure 3). As
previously shown,3 intravenous infusion of secretin did not
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increase bile and bicarbonate secretion in normal rats
(Table 1). Secretin increased bile and bicarbonate secretion in
normal rats treated with histamine compared with normal
rats treated with saline (Table 1), demonstrating that hista-
mine stimulates biliary hyperplasia by activation of cAMP-
dependent signaling.
In Vitro Studies Evaluation of Cholangiocyte
Proliferation and Signaling Mechanisms
Dose- and time-response experiments demonstrated that
histamine increases NRIC proliferation (by MTS assays)
compared with BSA-treated NRICs (Figure 4). As the sti-
mulatory effects of histamine on cholangiocyte proliferation
were seen as early as after 24 h of incubation, all other
stimulations were performed at 24 h at the histamine con-
centration of 10 mM, the smallest dose at which we observed a
stimulatory effect on NRIC proliferation. Furthermore, we
performed experiments aimed to demonstrate which HR
subtypes regulate histamine-stimulated NRIC proliferation.
Histamine, H1HR and H2HR (but not H3HR or H4HR)
agonists increased NRIC proliferation (Figure 5a). Histamine
stimulation of NRIC proliferation was blocked by terfenadine
Figure 1 (a) By immunohistochemistry in liver sections, both small (yellow arrow) and large (red arrow) bile ducts express H1–H4HRs. Original
magnification  40. (b) Frequency size distribution shows that NRIC are formed by both small and large NRICs. NRIC by immunofluorescence
(bar¼ 20 mm); DAPI staining is seen in blue, whereas the red staining represents the specific histamine receptor. A merged image is shown along with
negative staining. (c) By RT-PCR, purified pooled cholangiocytes from normal rats and NRICs expressed H1–H4HRs. By immunoblots, purified small and
large normal cholangiocytes expressed H1–H4HRs.
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(H1HR antagonist), cimetidine (H2HR antagonist) and at
the same extent by terfenadineþ cimetidine (Figure 5a),
demonstrating that both H1HR (by activation of Ca2þ
signaling; see Figure 6) and H2HR (by activation of cAMP
signaling; see Figure 6) mediate histamine-induced increase in
NRIC proliferation (Figure 5a). Furthermore, we demon-
strated that (1) H1HR and H2HR (in addition to histamine)
agonists stimulate NRIC proliferation (Figure 5b and c); (2)
H1HR-induced NRIC proliferation was blocked by BAPTA/
AM and Go¨6976 but not by Rp-cAMPs (Figure 5b); and
(3) H2HR-induced NRIC proliferation was blocked by
Rp-cAMPs but not BAPTA/AM and Go¨6976 (Figure 5c).
Measurement of IP3 and cAMP Levels and PKC and PKA
We demonstrated that HTMT dimaleate (H1HR agonist)
increases IP3 levels (Figure 6a) and PKC phosphorylation
(Figure 6c), whereas amthamine dihydrobromide (H2HR
agonist) enhances cAMP levels (Figure 6b) and PKA phos-
phorylation (Figure 6d). HTMT dimaleate did not alter
cAMP levels of NRIC, whereas amthamine dihydrobromide
did not change IP3 levels of NRIC (Figure 6a and b).
Effect of PKCa Silencing on NRIC Proliferation
With the finding that the H1HR agonist increased phos-
phorylation of PKCa, we sought to pinpoint the role of
Figure 1 Continued.
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Ca2þ -dependent PKCa (that has a key role in biliary
growth)14,39–44 on NRICs (after stimulation with HTMT
dimaleate) using siRNA transfection. In PKCa-siRNA
(1.0 mg)-transfected cells (90% knockdown efficiency,
Figure 7a), HTMT dimaleate failed to increase NRIC pro-
liferation (Figure 7b). As expected, in scrambled-transfected
NRICs, HTMT dimaleate increased NRIC proliferation
(Figure 7b).
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DISCUSSION
We have demonstrated that intrahepatic bile ducts, freshly
isolated cholangiocytes and NRICs express H1–H4HRs. We
have shown that histamine increases normal cholangiocyte
growth by interaction with H1HR and H2HR by activation of
both IP3/Ca
2þ - and cAMP-dependent mechanisms, respec-
tively. Furthermore, the H1HR agonist increases NRIC pro-
liferation by activation of IP3/Ca
2þ /PKCa-dependent
signaling likely targeting small Ca2þ -dependent NRIC.
When PKCa was silenced, the H1HR agonist did not increase
NRIC proliferation. In contrast, the H2HR (that signals
through activation of Gas)
23 induces normal cholangiocyte
growth by activation of a cAMP/PKA-dependent mechanism
(independent of PKCa) by likely targeting large cAMP-de-
pendent NRICs.
The finding that normal rat cholangiocytes and NRICs
express H1–H4HRs are supported by previous studies in
normal mouse15 and BDL rat cholangiocytes.16 Moreover, we
have previously demonstrated the expression of H3HR in
hyperplastic cholangiocytes and cholangiocarcinoma cells,
and defined the inhibitory role of H3HR in the growth of
hyperplastic and neoplastic cholangiocytes.16,45 HRs are also
expressed in the liver by hepatocytes that are activated by
endogenous histamine to release a wide array of effects.46,47
For example, histamine activates IP3 synthesis in guinea pig
hepatocytes by activation of H1HR47 and stimulates glyco-
genolysis in hepatocytes by interaction with H1HR by acti-
vating the Ca2þ messenger system.46
In animal models of cholangiocyte hyperplasia/loss, both
IP3/Ca
2þ - and cAMP-dependent signaling pathways regulate
the proliferative activities of small and large cholangiocytes,
respectively.3,8,9,16 For example, in the cholestatic BDL
model, there is marked proliferation of large cholangiocytes
by activation of cAMP signaling.3,8,16 With regard to IP3/
Ca2þ -dependent signaling, stimulation of small cholangio-
cyte growth (eg, after feeding of the bile salt, taurocholate)
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Figure 3 Evaluation of basal- and secretin-stimulated cAMP levels in
purified cholangiocytes from normal rats treated with saline or histamine
for 1 week. Histamine increased both basal- and secretin-stimulated cAMP
of normal cholangiocytes compared with cholangiocytes from normal rats
treated with saline. &Po0.05 vs basal cAMP levels of cholangiocytes from
normal rats treated with saline. *Po0.05 vs basal cAMP levels of
cholangiocytes from saline-treated normal rats. #Po0.05 vs secretin-
stimulated cAMP levels of cholangiocytes from saline-treated normal rats.
Data are mean±s.e.m. of six experiments.
Table 1 Measurement of basal- and secretin-stimulated bile flow, bicarbonate concentration and secretion in normal rats treated
with saline or histamine for 1 week
Bile flow Bicarbonate secretion
Treatment Basal
(ml/min per kg BW)
Secretin
(ml/min per kg BW)
Basal
(mEquiv./min per kg BW)
Secretin
(mEquiv./min per kg BW)
Normal rats+NaCl (n¼ 7) 68.3±6.2 73.6±7.0 2.3±0.2 2.5±0.2
Normal rats+histamine (n¼ 7) 74.5±4.8 90.5±5.2* 2.4±0.2 3.1±0.15*
BW, body weight.
When steady spontaneous bile flow was reached (60–70min from the infusion of Krebs–Ringer–Henseleit (KRH), rats were infused for 30min with secretin,
followed by a final infusion of KRH for 30min. Data are mean±s.e.m. *Po0.05 (by Student’s unpaired t-test) vs the corresponding basal value of bile flow or
bicarbonate secretion of normal rats treated with histamine for 1 week.
Figure 2 (a–c) Effect of chronic administration of saline, histamine, H1HR or H2HR agonists on small, large and pooled IBDM of normal rats.
(a) Administration of histamine and the H1HR agonist, HTMT dimaleate increased small IBDM of normal rats compared with saline-treated rats; the
H2HR agonist, amthamine dihydrobromide, did not alter small IBDM. (b) Histamine and amthamine dihydrobromide (but not HTMT dimaleate) increased
large IBDM of normal rats compared with control rats. (c) The IBDM of pooled bile ducts was increased by histamine and both H1 and H2HR agonists.
*Po0.05 vs small, large and pooled IBDM of normal rats. #Po0.05 vs small and pooled IBDM of normal rats. &Po0.05 vs large and pooled IBDM of normal
rats. Data are mean±s.e.m. Ten randomly selected portal tracts were evaluated in three different slides. *Po0.05 vs IBDM of normal rats treated with saline.
(d) There was a significant increase in PCNA protein expression in freshly isolated pooled cholangiocytes from normal rats treated with histamine, H1HR or
H2HR compared with vehicle-treated rats. *Po0.05 vs PCNA of cholangiocytes from normal rats treated with saline. Data are mean±s.e.m. of four
blots from several different and cumulative preparations of cholangiocytes.
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depends on the activation of the Ca2þ -dependent PKCa.41
Moreover, activation of a1-adrenergic receptors stimulate the
proliferation of small mouse cholangiocytes through Ca2þ -
dependent activation of NFAT2 and Sp1.48 In this study, we
demonstrate that histamine stimulates small and large biliary
growth by the differential activation of both Ca2þ and cAMP
signaling. One possible explanation for the differential effects
induced by histamine is likely due to the interaction with
specific HRs expressed by different-sized cholangiocytes, ie,
small and large. Indeed, we have shown that activation of
H1HR increases the proliferation of small cholangiocytes by
activation of IP3/Ca
2þ -CaMK I signaling.15 In addition, ac-
tivation of H3HR causes decreased large cholangiocyte hy-
perplasia by downregulation of cAMP-dependent signaling.16
Based on this, we propose that histamine-induced increases
in the proliferation of both small and large cholangiocytes
are mediated by activation of IP3/Ca
2þ signaling in small
cholangiocytes and NRICs (by likely interaction with H1HR)
and cAMP transduction pathways in large cholangiocytes and
NRICs (presumably mediated by H2HR). On the basis of this
rationale and these previous findings, we also propose that
the increase in secretin-stimulated choleresis (observed after
in vivo administration of histamine to normal rats) likely
depends on activation of H2HR in large cholangiocytes, the
only biliary cell type in the liver that functions by a cAMP-
dependent mechanism.1,6,8,11
We next performed in vitro studies in polarized NRICs
(which contain both small and large cholangiocytes, Figure
1b) and demonstrated that histamine activation of NRIC
proliferation is blocked by terfenadine (H1HR antagonist),
cimetidine (H2HR antagonist) and at the same extent by
simultaneous treatment with terfenadineþ cimetidine. A
shortcoming of this in vitro experiment is represented by the
fact that both H1HR and H2HR antagonists block com-
pletely the stimulatory effects of histamine on NRIC pro-
liferation, although one of the two receptors (H1HR or
H2HH) are still active during treatment with these two
inhibitors. We provide this explanation supported by
our previous findings.14,39,42,44,49,50 As we have previously
demonstrated that cross-talk between Ca2þ - and cAMP-
dependent signaling coordinately mediates biliary secretion
and growth,14,39,42,44,49,50 we propose that blockage of Ca2þ
(by the H1HR antagonist) and cAMP (by the H2HR an-
tagonist) signaling may reciprocally inhibit cAMP and Ca2þ
signaling, respectively. This explanation is also supported by
the fact that the inhibitory effects of terfenadine and cime-
tidine (when administered together) on NRIC proliferation
were not additive.
We have also shown that (1) histamine stimulation of
NRIC proliferation is dependent on the activation of both the
IP3/Ca
2þ and the cAMP signaling pathways (blockage by
both Ca2þ chelators and specific PKC and PKA inhibitors);
(2) H1HR stimulation of small cholangiocyte growth
Figure 4 Dose- and time-response experiments demonstrated that
histamine (at 10, 50 and 100 mM) increase NRIC proliferation (by MTS)
compared with NRIC treated with BSA. *Po0.05 vs proliferation of NRIC
treated in vitro with 0.2% BSA (basal). Data are mean±s.e.m. of seven
experiments.
Figure 5 (a) Histamine, H1HR and H2HR (but not H3HR or H4HR) agonists increased NRIC proliferation. Histamine stimulation of NRIC proliferation was
partly blocked by terfenadine and cimetidine. *Po0.05 vs proliferation of NRIC treated in vitro with 0.2% BSA (basal). Data are mean±s.e.m. of seven
experiments. H1HR agonist¼HTMT dimaleate; H2HR agonist¼ amthamine dihydrobromide; H3HR agonist¼ RAMH; H4HR¼ clobenpropit. (b and c) By
PCNA immunoblots, we demonstrated that: (b and c) H1HR and H2HR agonists (in addition to histamine) stimulate NRIC proliferation;
(b) H1HR-induced NRIC proliferation is blocked by BAPTA/AM and Go¨6976 but not Rp-cAMPs; and (c) H2HR-induced NRIC proliferation is
blocked by Rp-cAMPs but not BAPTA/AM and Go¨6976. *Po0.05 vs proliferation of NRIC treated in vitro with 0.2% BSA (basal). Data are mean±s.e.m.
of six experiments. H1HR agonist¼HTMT dimaleate; H2HR agonist¼ amthamine dihydrobromide.
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depends on the activation of IP3/Ca
2þ /PKCa signaling
(proliferation blocked by Ca2þ chelators and PKC but not by
PKA inhibitors); and (3) H2HR stimulation of large NRIC
proliferation is mediated by cAMP-dependent PKA signaling
(blockage by only PKA inhibitors). Further confirmation
of differential signaling was found with evaluation of
intracellular cAMP and IP3 levels, as well as PKCa and PKA
phosphorylation. H1HR stimulation activates IP3 levels and
PKCa phosphorylation, whereas H2HR increases cAMP
levels and PKA phosphorylation. The importance of signaling
through differential pathways is important because in cho-
langiopathies, there is proliferation/damage of only specific
bile ducts of different sizes.8,10,11,13,15,34 Cholangiopathies
target both small and large cholangiocytes,8,10,11,34 and, thus,
it may be important for histamine to have the ability to
modulate cholangiocyte proliferation and/or loss through the
activation of HRs that will induce stimulatory (H1 and H2H)
and inhibitory (H3 and H4HR) effects on biliary growth.
After finding that H1HR activates Ca2þ -dependent PKCa
and knowing that PKCa has a critical role in cholangiocyte
function,14,39,41,42,50 we knocked down PKCa expression and
evaluated the effect of HTMT dimaleate on NRIC prolifera-
tion. As no commercially kits are available for silencing PKA,
we could not evaluate the role of PKA silencing on H2HR-
induced large NRIC proliferation. Similar to what we have
previously shown45 in cholangiocarcinoma cells using the H3
agonist, RAMH, we found here that the reduction of PKCa in
NRICs ablates the stimulatory effects of HTMT dimaleate.
PKCa has a critical role in the function of numerous cells and
the loss of PKCa signaling can have a negative or positive
impact on the proliferation of a number of epithelial
including cholangiocytes.14,39–41,45,50 For example, PKCa
has a stimulatory role in wound healing of human corneal
epithelial cells after hepatocyte growth factor stimulation.51
In cancer, PKCa has a stimulatory role enhancing the growth
of certain cancers,52 whereas the activation of PKCa
Figure 6 Effect of H1HR and H2HR agonists on (a) IP3 levels and (b) cAMP levels, (c) PKC phosphorylation and (d) PKA phosphorylation in NRIC. We
demonstrated that HTMT dimaleate (a H1HR agonist) increases IP3 levels (a) and PKC (panel c) phosphorylation, whereas amthamine dihydrobromide
(a H2HR agonist) enhances cAMP levels (b) and PKA phosphorylation (d). *Po0.05 vs proliferation of NRIC treated in vitro with 0.2% BSA (basal).
Data are mean±s.e.m. of six experiments.
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modulates the inhibition of cholangiocarcinoma growth.42,45
Further studies are necessary to understand why activation of
PKCa in biliary cells induces either inhibition or activation of
hyperplastic and neoplastic biliary growth and secretin-sti-
mulated ductal secretion (a functional index of biliary hy-
perplasia).14,39,41–43,50 One potential explanation for the
differential effects of PKCa on biliary growth may depend on
the type of receptor (eg, M3 acetylcholine, insulin, gastrin or
a1-adrenergic) or transporter (eg, Naþ -dependent apical bile
acid transporter) that are upregulated or downregulated after
vagotomy, the treatment with the selected gastrointestinal
hormone or bile salt feeding.14,39,41–43,50 A possible short-
coming of our study is that PKCa may be not the only factor
as other Ca2þ -dependent (bI, bII and g) and Ca2þ -
independent (d, e, y, Z and z) PKC isoforms may be involved
in H1HR stimulation of biliary growth.
Taken together, these findings implicate histamine and
HRs as key factors in the regulation of normal cholangiocyte
proliferation and function. Although endogenous histamine
may activate numerous signaling mediators and pathways, it
may be more important that stimulation of specific HRs is
able to induce specific effects in target cells (possibly in small
and large subpopulations of cholangiocytes) using different
signaling pathways. In clinical situations in which certain
subpopulations of cells are affected, the usage of specific
agonists may help in the development of therapeutic treat-
ments. For example, in a cholestatic state in which inflamed
cholangiocytes are overproliferating, the usage of the H3HR
agonist RAMH might aid in patient therapy to help decrease
cholangiocyte proliferation. On the other hand, in a case of
damaged or cholangiocyte loss, treatment with either an
H1HR or H2HR agonist may increase proliferation when
warranted and necessary for recovery.
As histamine is released by mast cells,53 further studies are
warranted to evaluate how mast cells may be contributing to
cholangiocyte proliferation, a topic that is a topic of future
work in our laboratory. In support of this novel topic, it has
been demonstrated that during cholestasis, mast cell quan-
tities increase.53 Increased mast cell quantity would likely lead
to increased histamine release into the microenvironment,
thus modulating biliary functions. Furthermore, ongoing
studies from our laboratory aim to demonstrate that bile
acids (that have a key role in the regulation of biliary func-
tions and stimulate histamine secretion from mast
cells)40,41,44,50,54 affect cholangiocyte growth by releasing
histamine from proliferating mast cells.
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